TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,518,058 | -4.7% | 1,512,087 | +63.7% | 0.00% | 0.0% |
| Q2 2023 | $14,190,965 | -20.3% | 923,891 | +16.8% | 0.00% | -25.0% |
| Q1 2023 | $17,794,717 | -68.0% | 791,228 | -70.0% | 0.00% | -66.7% |
| Q4 2022 | $55,522,270 | -11.8% | 2,640,146 | +3.4% | 0.01% | -20.0% |
| Q3 2022 | $62,930,000 | -0.6% | 2,553,974 | -2.2% | 0.02% | +7.1% |
| Q2 2022 | $63,305,000 | -5.2% | 2,612,646 | +0.9% | 0.01% | 0.0% |
| Q1 2022 | $66,747,000 | -17.1% | 2,590,107 | -0.1% | 0.01% | -12.5% |
| Q4 2021 | $80,510,000 | +203.7% | 2,593,757 | +137.2% | 0.02% | +166.7% |
| Q3 2021 | $26,513,000 | -26.0% | 1,093,322 | -55.5% | 0.01% | -25.0% |
| Q2 2021 | $35,852,000 | +73.5% | 2,457,280 | +197.0% | 0.01% | +60.0% |
| Q1 2021 | $20,661,000 | +6.2% | 827,434 | +15.9% | 0.01% | 0.0% |
| Q4 2020 | $19,459,000 | – | 713,966 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |